From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Orforglipron trials with results
9 trials, 9,168 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| ATTAIN-1A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Orforglipron | 3,127 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (percent change), Baseline, Week 72. Placebo: -0.87; 6 mg Orforglipron: -7.82; 12 mg Orforglipron: -9.27; 36 mg Orforglipron: -12.35. |
| ACHIEVE-3A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron | 1,698 | Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide] (Percentage of HbA1c), Baseline, Week 52. 12 mg Orforglipron: -1.91; 36 mg Orforglipron: -2.16; 7 mg Semaglutide: -1.11; 14 mg Semaglutide: -1.45. |
| ATTAIN-2A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron | 1,613 | Percent Change From Baseline in Body Weight (percent change), Baseline, Week 72. Placebo: -2.21; 6 mg Orforglipron QD: -5.50; 12 mg Orforglipron QD: -7.78; 36 mg Orforglipron QD: -10.54. |
| ACHIEVE-2A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Orforglipron | 962 | Change From Baseline in HbA1c [Noninferiority Analysis] (percentage of HbA1c), Baseline, Week 40. Orforglipron 3 mg: -1.32; Orforglipron 12 mg: -1.74; Orforglipron 36 mg: -1.73; Dapagliflozin 10 mg: -0.76. |
| ACHIEVE-1A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Orforglipron | 559 | Change From Baseline in HbA1c (percentage of HbA1c), Baseline, Week 40. Placebo: -0.15; 3 mg Orforglipron: -1.26; 12 mg Orforglipron: -1.59; 36 mg Orforglipron: -1.45. |
| ACHIEVE-5A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Orforglipron | 546 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 40. Placebo: -0.77; 3 mg Orforglipron QD: -1.54; 12 mg Orforglipron QD: -2.05; 36 mg Orforglipron QD: -1.90. |
| ACHIEVE-JA Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Orforglipron | 401 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Participants), Baseline to Week 54. 3 mg Orforglipron: 107; 12 mg Orforglipron: 114; 36 mg Orforglipron: 118. |
| ATTAIN-JA Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Orforglipron | 238 | Percent Change From Baseline in Body Weight at Week 72 (percent change), Baseline, Week 72. Placebo QD: -0.63; 6 mg Orforglipron QD: -5.90; 12 mg Orforglipron QD: -8.69; 36 mg Orforglipron QD: -7.93. |
| NCT05936138A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment. | Orforglipron | 24 | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970 (nanogram*hour per milliliter (ng*hr/mL)), Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose. LY3502970 (Normal Renal Function): 113; LY3502970 (Severe Renal Impairment): 167; LY3502970 (End-Stage Renal Disease): 108. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.